News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
Subscribe To Our Newsletter & Stay Updated
